Literature DB >> 2925225

Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.

H Kitamura1, M Tsuboi.   

Abstract

A serum factor, which inhibits haemolysis of the buffer control used in a C3 haemolytic assay, was found in a C3-deficient subject (C3D). Since the buffer control consisted of EAC142, C5 and C6-9 reagent (C6-9R, prepared by treatment of guinea-pig serum with KSCN and hydrazine hydrate), the factor seems to be an inhibitor of C3-independent immune haemolysis. Gel filtration and CM cellulose column chromatography of C3D serum suggested that the inhibitor may be C8. The inhibition was not observed in C8-depleted C3D serum. Furthermore, isolated C8 was found to inhibit haemolysis of EAC142 by C5 and C6-9R in a dose-dependent fashion. Thus, C8 was found to be an inhibitor of C3-independent immune haemolysis in the assay. Further studies revealed that C8 also inhibits haemolysis of EAC142 by C3, C5 and C6-9R (C3 assay system) or that of EAC1423 by C5 and C6-9R (C5 assay system), indicating that C3 or C5 haemolytic activity can be underestimated by the presence of C8 in a sample. C8 did not inhibit haemolysis in the assay system when isolated C6-C9 of human origin were used, but did inhibit haemolysis when isolated C6-C9 of guinea-pig origin was used instead of C6-9R. Thus, it was suggested that the incompatibility of human C8 with guinea-pig C6-C9 might be responsible for this phenomenon. Additional experiments for the mechanism clearly showed that human C8 inhibits the haemolysis of EAC1-7 (EA bearing human C1-C5 and guinea-pig C6 and C7) by guinea-pig C8 and C9 by binding to EAC1-7 prior to guinea-pig C8.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925225      PMCID: PMC1385098     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.

Authors:  S Schönermark; S Filsinger; B Berger; G M Hänsch
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

2.  The ninth component of human complement: isolation, description and mode of action.

Authors:  U Hadding; H J Müller-Eberhard
Journal:  Immunology       Date:  1969-06       Impact factor: 7.397

3.  Studies on the C'3d of guinea pig complement.

Authors:  K Inoue; T Mori; K Yonemasu
Journal:  Biken J       Date:  1967-09

4.  C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3.

Authors:  H Kitamura; M Matsumoto; K Nagaki
Journal:  Immunology       Date:  1984-11       Impact factor: 7.397

5.  Deficiency of the ninth component of complement in man.

Authors:  S Inai; H Kitamura; S Hiramatsu; K Nagaki
Journal:  J Clin Lab Immunol       Date:  1979-04

6.  Further studies on C9 deficiency.

Authors:  H Kitamura; K Nagaki; S Inai
Journal:  J Clin Lab Immunol       Date:  1981-07

7.  Hereditary deficiency of the third component of complement in two sisters with systemic lupus erythematosus-like symptoms.

Authors:  Y Sano; H Nishimukai; H Kitamura; K Nagaki; S Inai; Y Hamasaki; I Maruyama; A Igata
Journal:  Arthritis Rheum       Date:  1981-10

8.  C56 formation in the reaction mixture of isolated complement components through the classical complement pathway.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

9.  C3-independent immune haemolysis: mechanism of membrane attack complex formation.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

10.  The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency.

Authors:  J A Manni; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more
  1 in total

1.  Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines.

Authors:  E Kitano; H Kitamura
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.